1.35%
1.74EUR
418MEUR
5.517BEUR
117.196M
About UCB
Sector
CEO
Jean-Christophe Tellier
Headquarters
Brussels
Website
Employees (FY)
8.703K
Founded
1925
ISIN
BE0003739530
UCB SA engages in the research and development biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.
UCB.BR short term bullish potential to challenge ATHConclusion:
A substantial break above 100, preferably above 107 signals a short term bullish potential, challenging ATH and beyond.
A drop below 75 on the other hand renders long term bearish or at least choppy consolidation.
For short term play targeting 108 minimally, with tight stop just under 96
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
